CLAUD-IT – Consortium Partners Website Tasks
Coordinator: European Institute for Biomedical Imaging Research (EIBIR)
Number of partners: 14 (13 beneficiaries, 1 affiliated entity)
Start date: 1st of September 2024
End date: 31st of August 2027
Total grant amount: 981 055,18€EU funding: 784 844,15€
CLAUD-IT supports EU Member States in the implementation of clinical audit in radiology and nuclear medicine. It brings together hospitals, authorities and societies to develop clinical audit guidelines and methodology, leading to improved healthcare and patient care across the EU.
The CLAUD-IT project is set to elevate patient care across Europe by supporting EU Member States in implementation of clinical audit, with a focus on radiology and nuclear medicine. CLAUD-IT connects hospitals, authorities, and societies in 9 EU Member States to develop clinical audit guidelines, methodology, and supporting documents. This initiative will train over 250 professionals, empowering them to lead audits and improve healthcare quality and safety across EU.
The CLAUD-IT project supports EU Member States in implementing clinical audits in radiology and nuclear medicine to improve the quality and safety of healthcare. It will pilot clinical audits in 9 EU Member States, starting with 11 hospitals and then expanding to a further 3-6 institutions in each participating country. The project, supported by the European Society of Radiology and the European Association of Nuclear Medicine, will use a phased approach and will train over 250 professionals through a train-the-trainer model to ensure further implementation of clinical audit in Europe. CLAUD-IT will also develop nuclear medicine guidelines and expand existing radiology guidelines based on the European Society of Radiology’s ESPERANTO for Radiology. All materials will be made available through an online repository, providing an open access one-stop-shop for clinical audit resources in radiology and nuclear medicine.
Objectives
- Assess the current state of the art in all 9 participating Member States to identify new developments since the completion of the QuADRANT project as well as existing infrastructures and stakeholders.
- Prepare practical, concise and evidence-based audit material and related training material for radiology and nuclear medicine and to make these available in a central repository in order to provide a “one-stop-shop” for stakeholders.
- Hold practical stakeholder training to conduct clinical audits under external guidance.
- Raise awareness for the importance of clinical audit by communicating its mandatory character as laid down in the BSSD and explaining the great impact it can have on daily professional practice as well as its contribution to higher quality care and patient safety. Convene the stakeholders in an effort to develop clinical audit strategies and campaigns.
CLAUD-IT is co-funded under the EU4Health Programme 2021–2027 under grant agreement no. 101160903.
Data Tools 4 Heart – A European Health Data Toolbox for Enhancing Cardiology Data Interoperability, Reusability and Privacy
Principal Investigator: Dott. Alfredo Cesario
VISION: Cardiovascular disease is the main cause of mortality worldwide, representing about a third of annual deaths, and patients’ medical care produces a large amount of data.
DataTools4Heart will design methods to reuse such data to facilitate research and improve the conditions of cardiovascular patients.
The DataTools4Heart toolbox will be designed, tested, and implemented in several countries while ensuring the compliance of all legal (e.g., privacy) constraints in the cardiology domain.
MISSION: DataTools4Heart aims to improve the lifestyle of patients suffering from cardiovascular diseases by developing a comprehensive, federated, privacy-preserving toolbox for data reuse in cardiology.
The tools include a platform that will securely access data from different hospitals and transform them into their digital counterparts (synthetic data) to be used by researchers and clinicians across the world. The access into large-scale multi-source cardiology data will be facilitated by the creation of virtual assistants.
FOCUS: Through the capacity of all its participants and the consortium, DataTools4Heart will focus on unlocking currently inaccessible cardiovascular health data.
DataTools4Heart operates in response to the European Society of Cardiology (ESC) call for a major shift towards integrative data-driven approaches to develop personalised cardiovascular medicine. Multi-site federated health data use will be allowed, thanks to the contributions from clinical centres from seven EEA countries, namely Spain, the Netherlands, United Kingdom, Italy, Sweden, Romania, and Czech Republic. They will constitute a representative sample of the European healthcare landscape, to contribute to the creation of the European Health Data Space.
OBJECTIVES: DataTools4Heart will create a comprehensive cardiology data toolbox for clinicians, researchers, and data scientists. Tools will allow data ingestion and harmonisation, Natural Language Processing in multiple languages, federated machine learning and data synthesis. Virtual assistants will aid users in navigating large multi-source cardiology data while adhering to European regulations and data standards.
DataTools4Heart is funded by the European Union’s Horizon Europe Framework Under Grant Agreement No. 101057849
Website: www.datatools4heart.eu
Budget: € 260.250
Duration: 01.10.2022 – 30.09.2023
Covid-X Personalized Care and Remote Support for Patients and Healthcare Workers at Covid-19 Risk.
Principal Investigator: Dott.Luca Tagliaferri
Ente Finanziatore: Commissione Europea – Horizon 2020
Budget: € 50.000
Duration: April 2021 – January 2022
Breve descrizione: COVID-X aims to provide competitive and market oriented European SMEs access to knowledge, technology, capital and markets with the aim to place new products/ services in the market with the goals of fighting the COVID-19 pandemic.
Website: https://www.covid-x.eu/
COVID-X has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101016065.
iHelp – Personalised Health Monitoring and Decision Support Based on Artificial Intelligence and Holistic Health Records
Principal Investigator: Prof. Vincenzo Valentini
Ente Finanziatore: Commissione Europea – Horizon 2020
Budget: € 482.222,50
Duration: 01/01/2021 – 31/12/2023
Description: The specific focus of iHELP is on early identification and mitigation of the risks associated with Pancreatic Cancer based on the application of advance AI-based learning and decision support techniques on the historic (primary) data of Cancer patients gathered from established data banks and cohorts. This analysis helps to (i) determine key risks associated with Pancreatic Cancer, (ii) develop predictive models for identified risks, and (iii) develop adaptive models for targeted prevention and intervention measures. Based on these developments, the project selects high-risk individuals that are invited to take part in the pilot activities or digital trials. The digital trials are carried out through user-centric mobile and wearable applications that apply proven usability principles to offer more awareness, more engaging experience for health monitoring, risk assessment and personalised decision support. Close collaboration between clinical and AI experts focus on drawing decision support against identified/predicted risks and providing personalised recommendations (e.g. lifestyle changes, behavioural nudges, screening test etc) to the participants in the digital trials. The iHELP (mobile and wearable) technology solutions help in validating iHELP solutions and raising health related awareness at individual level. The (secondary) data gathered through the mobile and wearable applications (concerning life style, behavioural, social interactions and response to targeted prevention and intervention measures) is integrated with primary data in the standardised HHR format – within a big data platform. Frugal AI-based learning techniques are developed to provide near real-time risk assessment based on the integrated and standardised HHR data. iHELP solutions are targeted at multiple stakeholders, including policymakers that will get decision support on the design of new screening programs and new guidelines for bringing improvements in clinical and lifestyle aspects.
iHelp has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101017441
Website: www.ihelp-project.eu
RE-SAMPLE: REal-time data monitoring for Shared, Adaptive, Multi-domain and Personalised prediction and decision making for Long-term Pulmonary care Ecosystems
Principal Investigator: Prof. Luca Richeldi
Ente Finanziatore: Commissione Europea – Horizon 2020
Budget: € 690.625
Duration: 01.03.2021 – 28.02.2025
Description: Real-world data and AI to enable tailored-made care for patients with COPD and comorbid complex chronic conditions (CCCs)
Over the course of four years (2021-2025), RE-SAMPLE will work to transform the healthcare journey of patients with Chronic Obstructive Pulmonary Disease (COPD) and comorbidities, and to set a standard of care for patients suffering from complex chronic conditions.
Using Artificial Intelligence (AI), RE-SAMPLE hopes to gain unique insights into the complex relationships between patients’ clinical and non-clinical characteristics, and how these impact disease progression, mental wellbeing, and physical health. The data and analyses will also serve as a basis for predictive models that will help patients and their doctors make treatment and lifestyle changes in time to reduce serious complications. One of the project’s hallmarks is the early integration of security and privacy settings across all technical (the system itself will be designed from this perspective) and non-technical (the project will adhere to rigorous ethical and data protection standards) aspects of RE-SAMPLE.
Website: www.re-sample.eu
RE-SAMPLE has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 965315.
TERMINET – nexT gEneRation sMart INterconnectEd ioT
Principal Investigator: Prof. Vincenzo Valentin
Ente Finanziatore: Commissione Europea – Horizon 2020
Budget: € 103.125
Duration: 01/11/2020 – 31/10/2023
Description: The vision of TERMINET is to provide a novel next generation reference architecture based on cutting-edge technologies such as SDN, multiple-access edge computing, and virtualisation for next generation IoT, while introducing new, intelligent IoT devices for low-latency, market-oriented use cases..
TERMINET’s primary intention is to bring (more efficient and accurate) decisions to the point of interest to better serve the final user targeting at applying distributed AI at the edge by using accelerated hardware and sophisticated software to support local AI model training using federated learning. Our solution aspires to reduce the complexity of the connecting vast number of heterogeneous devices through a flexible SDN-enabled middleware layer. It also aims to design, develop, and integrate novel, intelligent IoT devices such as smart glasses, haptic devices, energy harvesting modules, smart animal monitoring collars, AR/VR environments, and autonomous drones, to support new market-oriented use cases. Great expectation of the proposal is to foster AR/VR contextual computing by demonstrating applicable results in realistic use cases by using cutting-edge IoT-enabled AR/VR applications. By designing and implementing an IoT-driven decentralised and distributed blockchain framework within manufacturing, TERMINET aims to support maintenance and supply chain optimisation. Our solution intends to apply a vertical security by design methodology by meeting the privacy-preserving and trust requirements of the NG-IoT architecture. To foster standardisation activities for the IoT ecosystem, TERMINET will provide novel disruptive business models. For the evaluation of its wide applicability, TERMINET will validate and demonstrate six proof-of-concept, realistic use cases in compelling IoT domains such as the energy, smart buildings, smart farming, healthcare, and manufacturing.
Terminet has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 957406
Website: https://terminet-h2020.eu
PANACEA – Protection and privAcy of hospital and health iNfrastructures with smArt Cyber sEcurity and cyber threat toolkit for dAta and people (GA. 826293)
Ente Finanziatore: Commissione Europea – Horizon 2020 – SC1
Finanziamento: € 515.937,50
Durata: 01/01/2019 – 31/12/2021
Breve descrizione: Il progetto PANACEA fornirà soluzioni innovative di cybersecurity per il settore sanitario nelle aree strategiche di valutazione e mitigazione del rischio, blockchain per la condivisione delle informazioni, identificazione/autenticazione, modelli di decisione di comportamenti sicuri. Sarà sviluppato inoltre un sistema di simulazione delle numerose postazioni informatiche presenti in ospedale: “un’intelligenza esperta” esaminerà e indagherà, giorno e notte, le eventuali falle e i punti deboli da rinforzare nel sistema di sicurezza. L’ospedale, e in particolare le attività connesse all’urgenza, costituiranno un’area di prova di resistenza agli attacchi informatici che saranno simulati da esperti per verificare l’efficacia delle soluzioni di protezione proposte dal progetto . Maggiori informazioni sono disponibili su panacearesearch.
Italian General Practitioner databaSe for estimation and impact of advanced fibrosis in NAFLD: prevalence of advanced fibrosis (F>3) and clinical outcomes in unselected general population from a network of 1.000 GPs in Italy
Ente Finanziatore: GILEAD Sciences
Finanziamento: € 256.440,80
Durata: 05/10/2018 – 04/10/2020
Breve descrizione: La steatosi epatica non alcolica (NAFLD) è caratterizzata dall’eccessivo accumulo di trigliceridi nel fegato ed è spesso associata alla resistenza all’insulina e alla sindrome metabolica. Può evolvere nella steatoepatite non alcolica (NASH) con l’inizio di processi di rimodellamento della matrice che portano alla deposizione di fibrosi. Sfortunatamente, la diagnosi di NASH e la valutazione della fibrosi richiedono una biopsia epatica che rappresenta un esame invasivo con potenziali complicanze. Questo progetto vuole verificare la prevalenza di fibrosi in pazienti affetti da NAFLD utilizzando metodi di analisi non invasivi, sia strumentali sia utilizzando combinazioni di parametri clinici e bio-temporali.
Role of beta cell dedifferentiation in human type 2 diabetes
Principal Investigator: Dott.ssa Francesca Cinti
Ente Finanziatore: EFSD – European Foundation for the Study of Diabetes
Finanziamento: $ 75.000,00
Durata: 07/08/2018 – 06/08/2021
Breve descrizione: Le Cellule staminali pluripotenti indotte (iPSCs)rappresentano un modello affidabile per testare terapie farmacologiche e analizzare il meccanismo molecolare alla base delle malattie in un sistema che ospita le informazionigenetiche dei pazienti. Questo progetto intende utilizzare le iPSCs per per indagare e fornire collegamenti clinici, molecolari e genetici di innervazione e β-dedifferenziazione cellulare nel diabete di tipo 2 umano.